Pay in 4 interest-free payments of $5.59 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
Retatrutide is an investigational medication not approved by the FDA as of June 2026
Recognizing Serious Signs: When Bruising Needs Medical Attention Large expanding bruises, severe pain, numbness, or loss of function at the injection site require prompt evaluation
Lillys phase 3 ATTAIN-1 results, later published in The New England Journal of Medicine via PubMed, reported average weight loss of 12.4% at the highest dose over 72 weeks in adults with obesity or overweight without type 2 diabetes
10.1021/acs.chemrestox.9b00488 11
Standard Therapeutic Cycle (12 Weeks): Clinical trials frequently employed 12-week protocols, which provide sufficient duration for measurable metabolic changes while establishing safety through comprehensive monitoring
US$ 24.40
US$ 29.05
US$ 22.32
